Search results
Results from the WOW.Com Content Network
Pages in category "Drugs developed by Pfizer" The following 200 pages are in this category, out of approximately 240 total. This list may not reflect recent changes .
The headquarters of Pfizer in Tokyo, Japan. Pfizer Inc. (/ ˈ f aɪ z ər / FY-zər) [3] is an American multinational pharmaceutical and biotechnology corporation headquartered at The Spiral in Manhattan, New York City.
In the EU, abrocitinib is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy. [9]In the US, abrocitinib is indicated for the treatment of people twelve years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics ...
This category reflects the organization of Anatomical Therapeutic Chemical Classification System code D. Generally, drugs outlined within the ATC code D should be ...
Wyeth discovered and initially developed the drug, and clinical development continued after that company was acquired by Pfizer.Fezakinumab, in combination with methotrexate, completed a phase II trial in rheumatoid arthritis, [3] but data were not released.
When used as drugs, the International Nonproprietary Names (INNs) end in -mab. The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies.
Ozoralizumab (trade name Nanozora) is a trivalent anti-tumour necrosis factor alpha (TNFα) nanobody designed for the treatment of inflammatory diseases. [1]Ozoralizumab was developed by Pfizer Inc, and now belongs to Ablynx NV.
The drug was assumed to be potential $2bn-a-year blockbuster, when Pfizer acquired Anacor Pharmaceuticals. [12] However, the drug was commercially not successful, reaching only US$147 million in sales in 2018, and US$138 million in sales in 2019.